Bristol Myers Squibb
Camzyos
Hypertrophic Cardiomyopathy
Resolved
100days ago
Phase 2 readout · Mar 29, 2026
What's at stake
Phase 2 trial results for Camzyos in Hypertrophic Cardiomyopathy are due Mar 29, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Announced positive data from the Phase 3 SCOUT-HCM trial of Camzyos, the first study of a cardiac myosin inhibitor in adolescents (ages 12 years to <18 years) with symptomatic obstructive hypertrophic cardiomyopathy.”